The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations

After remaining steady in the first three sessions of the week ended September 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related, the news flow was fairly light ahead of the Labor Day holiday.

Amarin Corporation plc. (AMRN) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off.

Here are the key catalysts for the unfolding week.

Conferences

  • Citi's 15th Annual BioPharma Conference: September 8-11.
  • Wells Fargo 2020 Virtual Healthcare Conference: September 9-10.
  • Baird 2020 Global Healthcare Conference: September 9-10.
  • BTIG Virtual Biotechnology Conference: September 10-11.
  • 66th Annual Meeting of the American Rhinologic Society, or ARS, (virtual event): September 10-12.
  • International Gynecologic Cancer Society, or IGCS, xDigital Annual Global Meeting: September 10-13.
  • 2020 Psych Congress (virtual event): September 10-13.
  • MDS Virtual Congress 2020: September 12–16.
  • MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting: September 11-13.

PDUFA Dates

The FDA is set to rule on Mallinckrodt PLC (MNK)'s NDA for terlipressin, which is being evaluated for treating hepatorenal syndrome type 1 on Saturday, September 12.

Clinical Readouts/Presentations

Standalone Releases:

  • Applied Genetic Technologies Corp. (AGTC) said it will present an update on Wednesday, September 9 on its planned Phase 2/3 X-Linked Retinitis Pigmentosa clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5.

MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting Presentations:

  • Johnson & Johnson (JNJ)'s Janssen unit: additional data on the effect of treatment with ponesimod versus teriflunomide on disability measures in patients with relapsing multiple sclerosis.
  • Roche Holdings AG (RHHBY)'s Genentech unit: New analyses from the two-year open-label Phase 3b CASTING study of Ocrevus in patients with relapsing-remitting multiple sclerosis, and new data from the SAkura Phase 3 studies of Enspryng in neuromyelitis optica spectrum disorder.
  • Atara Biotherapeutics Inc. (ATRA): Presenting new 12-month data from all four cohorts in the Phase 1a study of ATA188 for the treatment of progressive forms of multiple sclerosis on Friday, September 11.
1 2
View single page >> |

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.